Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Has Average Price Target of $43.73 According to Brokerages

03 Oct 2026, 06:45 by Michael Walen · The Markets Daily

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) has received an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $44.67.

TEVA has been the topic of a number of research reports. Leerink Partners began coverage on Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. Wall Street Zen lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. TD Cowen started coverage on Teva Pharmaceutical Industries in a research report on Thursday. They set a “buy” rating and a $55.00 price objective for the company. Weiss Ratings downgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, September 8th. Finally, Piper Sandler increased their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th.

Check Out Our Latest Research Report on TEVA

Insider Activity

In other news, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the transaction, the insider owned 8,500 shares in the company, valued at approximately $330,225. This represents a 46.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roberto Mignone sold 367,600 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 374,959 shares of company stock valued at $14,644,285 in the last 90 days. Insiders own 0.54% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the company. WCM Investment Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after acquiring an additional 26,813,522 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its position in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares during the period. Castle Hook Partners LP bought a new position in Teva Pharmaceutical Industries during the 4th quarter valued at $82,013,000. Capital World Investors acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $73,687,000. Finally, SEB Asset Management AB acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $59,551,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $39.48 on Wednesday. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a fifty-two week low of $18.83 and a fifty-two week high of $40.79. The firm has a 50-day simple moving average of $37.04 and a 200 day simple moving average of $34.12. The company has a market cap of $46.01 billion, a PE ratio of 65.80, a P/E/G ratio of 3.75 and a beta of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion for the quarter. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 1.93 EPS for the current year.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

Positive Sentiment: Ecopipam data strengthen Teva’s pipeline prospects. New analyses showed that approximately 70% of pediatric Tourette syndrome patients experienced clinically meaningful tic reduction within eight weeks. An interim 18-month extension study showed a mean 45.6% reduction in tic-severity scores, with no new safety signals. The results support ecopipam’s potential as a differentiated, non-antipsychotic treatment, although it remains investigational and is not yet approved. Teva Presents New Efficacy and Safety Data with Ecopipam
Positive Sentiment: Analyst sentiment improved. TD Cowen initiated coverage with a Buy rating and a $55 price target, implying substantial upside from the recent trading level. Separately, the reported consensus target increased 24.24% to approximately ₪41.82, reinforcing a favorable view of Teva’s valuation and growth outlook.
Positive Sentiment: Biosimilar collaboration expands future growth opportunities. Teva and Samsung Bioepis agreed to develop and commercialize up to six biosimilar candidates globally, including candidates referencing Fasenra and Ilaris. The agreement could broaden Teva’s specialty-medicine pipeline and support longer-term revenue growth, though development and regulatory milestones remain ahead. Samsung Bioepis and Teva Expand Strategic Partnership
Neutral Sentiment: A Journal of Child Neurology review highlighted ecopipam’s selective D1-receptor mechanism and potential advantages over antipsychotic therapies, but the review is supportive scientific context rather than new clinical or regulatory approval. Journal of Child Neurology Review

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.